SEC Filing Analysis: HERON THERAPEUTICS, INC. /DE/ (HRTX)

Executive Summary

• Trading Significance: Low
• Key Takeaway: The EVP, Chief Financial Officer, Ira Duarte, acquired 11,694 shares of common stock through the vesting of Restricted Stock Units (RSUs), a routine compensatory event with no cash value exchanged.
• Market Impact: Neutral. This transaction is a standard part of an executive compensation package and is not indicative of new insider sentiment.

Company Information

Field	Value
Company	HERON THERAPEAUTICS, INC. /DE/
Ticker Symbol	HRTX
CIK	0000818033
Industry	PHARMACEUTICAL PREPARATIONS

Insider Information

Field	Value
Name	Duarte Ira
CIK	0001488864
Title/Position	EVP, Chief Financial Officer
Relationship	Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-10-31
Transaction Code	M (Exercise/Vesting)
Security Type	Common Stock
Shares Involved	11,694
Price Per Share	$0.00
Total Value	$0
Shares Owned After	179,786
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$0
% of Market Cap	0.0%
Shares Transacted	11,694
% of Shares Outstanding	0.006%
Post-Transaction Ownership	179,786 shares (0.098% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: Heron Therapeutics has a market capitalization of approximately $0.21 billion. The transaction value is $0, making it financially immaterial.
• Ownership Concentration: The CFO's post-transaction ownership of 0.098% is not a controlling stake and the increase is negligible.
• Dilution Impact: The vesting of 11,694 shares represents a minimal dilution of 0.006% to existing shareholders. This event was likely already factored into the company's fully diluted share count.
• Transaction Significance: The transaction is classified as low significance as it falls far below the materiality thresholds for both value as a percentage of market cap and shares as a percentage of outstanding stock.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: This is a non-discretionary transaction resulting from a pre-existing compensation agreement (vesting of RSUs). It does not reflect a new investment decision by the insider and is a common occurrence for public company executives.

Volume & Sentiment

• Expected Volume Impact: None. As this is not an open-market transaction, it will not directly impact trading volume.
• Sentiment Indicator: Neutral. The market generally does not react to routine RSU vesting events.

Additional Context

Transaction Notes

• Footnotes: The filing indicates the transaction is the result of RSU vesting. Footnote F2 clarifies the vesting schedule, noting units vest in 16 equal quarterly installments, confirming the routine nature of this event.